Study of the Anti-tumoral Immune Response (ERISA)

Centre Hospitalier Universitaire de Besancon

Status

Completed

Conditions

Breast Cancer

Glioma

Treatments

Other: additional blood sample

Study type

Interventional

Funder types

Other

Identifiers

NCT02854644

P/2013/188

Details and patient eligibility

About

This study evaluates the frequency of the spontaneous T cells specific CD4 answers of tumoral antigens breast cancer and glioma.

Enrollment

167 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Performance status 0,1 or 2
breast cancer or glioma
Arm glioma: patients without anti-tumoral treatment
Arm breast cancer: inclusion before treatment
Arm breast cancer HER2: patients with current therapy

Exclusion criteria

Psychiatric disease compromising the understanding of the information or the realization of the study
vulnerable People according to the law (minors, adults under protection, private persons of freedom ...)
Unaffiliated People to the Social Security
People being for the period of exclusion from another study
Life expectancy estimated unless 3 months.
For patients in Arm glioma: patients having already begun a systematic treatment.
For patients with a breast cancer: patient already under current therapy

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

167 participants in 4 patient groups

glioma

Experimental group

Description:

1 additional blood sample for patients with glioma and without treatment

Treatment:

Other: additional blood sample

breast cancer

Experimental group

Description:

2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.

Treatment:

Other: additional blood sample

breast cancer HER2+

Experimental group

Description:

1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression

Treatment:

Other: additional blood sample

Breast Cancer HER 2+ or HER2 triple -

Experimental group

Description:

1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant